On the 20% margin guidance excluding semaglutide, how do we improve from the current high-teens adjusted margin given uncertainty on semaglutide return?

Underlying margin this quarter was around 18%, similar to 19% last quarter. We maintain we are in the neighbourhood of 20% and likely to stay; with semaglutide resumption in November margins will be higher.

On abatacept plant inspection, how do the 7 observations compare with the last inspection (5 observations), and what type of queries are being received from FDA on the BLA?

The 7 observations are very different and addressable; we have responded within timelines. No queries received on the BLA as of now; goal date remains December 2026.

Why has the US base business lagged peers in R&D productivity over the past 4-5 years, and have there been issues in complex generics?

Yes, we failed in some complex generics (iron sucrose, conjugated estrogen, some peptides). We believe we have corrected these productivity issues and the R&D spend today is for products launching 10-12 years from now.

How many semaglutide pens were sold before the halt, and what gives confidence in the 6-7 million pen target for Nov-Mar given competitors?

Sold 180,000 pens before stopping. The 6-7 million pen demand is backed by orders; most markets will see limited new entrants during the gap, and our partners are waiting for our API.

What is the probability of resolving the semaglutide API root cause by the September timeline?

Success rate is high, somewhere between 80% to 90%. There is a chance it may fail, but we feel relatively confident.

Dr Reddy's Labs Q1 FY27 Earnings Call — Analysis (NSE: DRREDDY)

Semaglutide API setback drives ₹240 Cr provision and margin miss, but base business ex-lenalidomide grows double-digit and semaglutide supplies expected to resume in November.

28 Jul 2026 · Analysis by Alpha Inflection

The take

Q1FY27 Consolidated Revenues ₹8,071 Cr ( -5.6% YoY ) . New guidance — Q3FY27-Q4FY27 semaglutide injection supply vo… 6-7 million pens . New story: US generics base business reset .

Results

Revenue ₹8,071 Cr -5.6% YoY; EBITDA margin 12.5% (-1416 bps YoY), hit by semaglutide provision and Middle East conflict costs; net profit ₹443 Cr.

Financial highlights

Dr Reddy's Labs Q1 FY27 reported figures
Metric	Value	Change	Basis
Consolidated Revenues	₹8,071 Cr	-5.6%	yoy · Q1FY27 · YoY
EBITDA Margin	12.5%	-1416 bps	yoy · Q1FY27 · YoY
Net Profit	₹443 Cr		none · Q1FY27 · Q1FY27
North America Generics Revenue	US$236 million	-41%	yoy · Q1FY27 · YoY
India Revenue	₹1,718 Cr	+17%	yoy · Q1FY27 · YoY
Emerging Markets Revenue	₹1,833 Cr	+31%	yoy · Q1FY27 · YoY
Europe Revenue	€131 million	+broadly in line	yoy · Q1FY27 · YoY
PSAI Revenue	US$91 million	-5%	yoy · Q1FY27 · YoY
Gross Margin	46.5%	-1039 bps	yoy · Q1FY27 · YoY
R&D Spend	₹577 Cr	-8%	yoy · Q1FY27 · YoY
Capex (Cash Outflow)	₹307 Cr		point_in_time · Q1FY27 · Q1FY27
Net Cash Surplus	₹3,057 Cr		point_in_time · As of Jun 30, 2026 · June 30, 2026

Guidance

FY27 EBITDA margin ex-semaglutide and Middle East impact maintained in neighbourhood of 20%; semaglutide resumption by Nov with 6-7M pens expected Nov-Mar.

What management committed to

We are planning to resume semaglutide commercial supplies by November. — November 2026
We will be able to give to the market 6 to 7 million [semaglutide] pens between November and March. — 6-7 million pens, Q3FY27-Q4FY27
We are in the neighbourhood of the 20% [EBITDA margin] and likely to stay. — around 20%, near-term
The goal date for [abatacept] is still in December and this is still intact. — December 2026
[US Generics excluding lenalidomide] will continue double-digit growth throughout the year. — double-digit, FY27

Key themes

Semaglutide setback and recovery, base business resilience

How the narrative shifted

US generics base business reset: Now explicitly separates lenalidomide from base business to show underlying growth.
gRevlimid exclusivity as bridge: Shifted from a growth driver to a headwind reference.
Regulatory overhang on manufacturing: New facility observation expanded the regulatory narrative from the API facility to the biologics plant.
Cost rationalization to protect margins: Now quantifies the SG&A growth gap at 10-12% and ties it to branded market expansion.
Semaglutide API manufacturing disruption: Quantified lost opportunity (3-4M pens) and provided a confidence range of 80-90% on resolution.
Biosimilars and biologics build-out: New thread establishing biologics as a future profit driver.
Tariff and trade policy uncertainty: New macro thread introduced to address a specific policy risk.

Operational commentary

Semaglutide API scale-up failure led to ₹240 Cr provision, suspension of commercial supplies; root cause identified, resolution expected by late September, commercial resumption planned for November.
Underlying base business (ex-lenalidomide) delivered double-digit growth across all key geographies, including North America.
US generics launched two complex generics: bosutinib (first-to-market, 180-day exclusivity on 400 mg) and nintedanib.
Canada: first to launch semaglutide, sold 180,000 pens before halt, maintained Sandoz partnership.
India business grew 17% (organic 15.5%), supported by innovation franchise, new launches, and volume growth; toripalimab exceeded ₹100 Cr sales.
Emerging Markets grew 31% YoY, with 43 new product launches; aided by new products and favorable currency.
Europe NRT integration completed; change in operating model profit neutral; underlying NRT growth momentum intact.
Biologics facility Bachupally received USFDA PLI with 7 observations; response submitted; abatacept BLA goal date mid-Dec 2026, filed solely from Bachupally.
Capex guidance reduced to ₹1,800 Cr for FY27 vs earlier ~₹2,500-2,700 Cr levels; focused on biosimilars and peptides.
New partnership with Innoviva Specialty Therapeutics for XACDURO in Latin America/CIS; zoliflodacin Thai FDA approval achieved.
Semaglutide filings in 30+ markets; Brazil approval expected shortly; market demand remains strong for expected 6-7M pens Nov-Mar.
Middle East conflict increased solvent and freight costs, impacting EBITDA by ~1%, expected to persist through Dec 2026.

Analyst Q&A

Q. On the 20% margin guidance excluding semaglutide, how do we improve from the current high-teens adjusted margin given uncertainty on semaglutide return?
Underlying margin this quarter was around 18%, similar to 19% last quarter. We maintain we are in the neighbourhood of 20% and likely to stay; with semaglutide resumption in November margins will be higher.
Q. On abatacept plant inspection, how do the 7 observations compare with the last inspection (5 observations), and what type of queries are being received from FDA on the BLA?
The 7 observations are very different and addressable; we have responded within timelines. No queries received on the BLA as of now; goal date remains December 2026.
Q. Why has the US base business lagged peers in R&D productivity over the past 4-5 years, and have there been issues in complex generics?
Yes, we failed in some complex generics (iron sucrose, conjugated estrogen, some peptides). We believe we have corrected these productivity issues and the R&D spend today is for products launching 10-12 years from now.
Q. How many semaglutide pens were sold before the halt, and what gives confidence in the 6-7 million pen target for Nov-Mar given competitors?
Sold 180,000 pens before stopping. The 6-7 million pen demand is backed by orders; most markets will see limited new entrants during the gap, and our partners are waiting for our API.
Q. What is the probability of resolving the semaglutide API root cause by the September timeline?
Success rate is high, somewhere between 80% to 90%. There is a chance it may fail, but we feel relatively confident.

View source

Research and educational content only. Not investment advice.